|
The “Psoriasis Drugs Market: 2025 – 2035 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the psoriasis drugs ecosystem including psoriasis disorders, types of treatment options, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for psoriasis drugs from 2025 through to 2035. The forecasts are further segmented by 4 therapeutic classes, 3 routes of administration, 4 distribution channels, 5 regions and 26 leading countries.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report, and 2025 clinical drug development pipeline dataset profiling 51 future candidates.
|
For Enquiries, Press, Sample Pages and Table of Contents Please Contact: [email protected]
The Psoriasis Drugs Market: 2025 – 2035 - Opportunities, Challenges, Strategies & Forecasts
|
Synopsis: Psoriasis is a chronic inflammatory skin disorder affecting more than 125 million people globally, including over 8 million in the United States. Characterized by thick, reddened, scaly plaques that cause itching and pain, the disease imposes substantial physical, psychosocial, and economic burdens across all severity levels. Growing public awareness and rising expectations around skin, hair, and nail appearance have increased the number of patients seeking more effective and durable treatment options.
Disease management is lifelong and focuses on achieving remission by slowing excessive skin-cell turnover and reducing inflammation. Treatment selection depends on disease type, body-surface involvement, and overall severity. Mild disease is typically managed with topical therapies, whereas moderate-to-severe psoriasis often requires oral systemics, biologics, or combination approaches. Over the past decade, psoriasis treatment has shifted from broad immunosuppression to highly selective therapies. Established biologics (TNF, IL-12/23, IL-17, and IL-23 inhibitors) have been complemented by oral small molecules (notably TYK2 inhibitors) and next-generation biologics. These innovations are achieving unprecedented complete skin clearance rates (PASI 100), extended duration of response, and improved convenience and safety profiles. As a result, they are driving stronger market growth, expanding the treatable patient population, and significantly increasing payer and physician expectations for long-term disease modification in psoriasis. SNS Research estimates that the psoriasis drugs market will account for nearly $20 Billion in revenue by the end of 2025. Despite challenges relating to drug stability and patent disputes amongst competition, the market is poised for significant growth over the forecast period, fueled by several novel agents advancing through late-stage development. |
Pricing: Single User to Global Access
Single User License: USD 2,500 Company Wide License (Single Site): USD 3,500 Company Wide License (Global Site): USD 6,500 For a Sample and Table of Contents please contact: [email protected] Topics Covered:
The report covers the following topics:
Sample Figure: Psoriasis Drugs Development Pipeline Breakdown by Therapeutic Area (%)
|
The “Psoriasis Drugs Market: 2025 – 2035 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the psoriasis drugs ecosystem including psoriasis disorders, types of treatment options, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for psoriasis drugs from 2025 through to 2035. The forecasts are further segmented by 4 therapeutic classes, 3 routes of administration, 4 distribution channels, 5 regions and 26 leading countries.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report, as well as an Excel sheet covering clinical drug development pipeline for the psoriasis drugs market, profiling 51 future candidates.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report, as well as an Excel sheet covering clinical drug development pipeline for the psoriasis drugs market, profiling 51 future candidates.
For a Sample and Table of Contents please contact: [email protected]
|
Key Findings:
The report has the following key findings:
|
Key Questions Answered:
The report provides answers to the following key questions:
Sample Figure:
Sample Figure: Distribution of Psoriasis Pipeline Candidates by Developmental Phase (%)
|
Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
Market forecasts are provided for each of the following submarkets and their subcategories:
|
|
|
For a Sample and Table of Contents please contact [email protected]
List of Companies & Organizations:
All the companies and organizations mentioned in the report are listed below:
All the companies and organizations mentioned in the report are listed below:
|
Abbott Laboratories
AbbVie AbGenomics International Acelyrin Aclaris Therapeutics Actelion Pharmaceuticals Akeso Biopharma Akros Pharma Akzo Nobel Group Almirall AltruBio Alumis (Previously Esker Therapeutics) Alvotech Amgen Anacor Pharmaceuticals AnaptysBio Arcutis Biotherapeutics Artax Biopharma Artelo Biosciences AstraZeneca Azora Therapeutics Bausch & Lomb Bausch Health Bausch Health Ireland Limited Bayer Biocad Biocon Biologics Biofrontera AG Biogen BioMimetix Biosintez Bio-Thera Solutions BMS (Bristol-Myers Squibb) Boehringer Ingelheim Boston Pharmaceuticals Botanix Pharmaceuticals Cadila Healthcare Cadila Pharmaceuticals Can-Fite BioPharma Cantargia Celgene Corporation Celltrion Healthcare |
Cerbios-Pharma
Cipher Pharmaceuticals Coherus BioSciences Dermata Therapeutics DICE Therapeutics (Acquired by Eli Lilly) Dr. Reddy’s Laboratories Dusa Pharmaceuticals Eli Lilly and Company Enavate Sciences Encore Dermatology EPI Health European Medicines Agency (EMA) FDA Galderma Galectin Therapeutics Glenmark Pharmaceuticals GSK (GlaxoSmithKline) Hanwha Pharmaceutical Immutep Innovent Biologics InSite Vision Issar Pharma Janssen Biotech Janssen Pharmaceutical Janssen Research & Development Japan Tobacco (JT) Jiangsu Hengrui Pharmaceuticals Co. Johnson & Johnson Kyongbo Pharm Kyowa Kirin LEO Pharma Lipidor AB Mabpharm Maruho Mayne Pharma Group MC2 Therapeutics Meiji Seika Pharma Merck Merck & Co. MIT MoonLake Immunotherapeutics Mylan |
Nestle Skin Health
Novartis Ono Pharmaceutical Ortho Dermatologics Pelthos Therapeutics (Part of Ligand Pharmaceuticals) Pfizer Pharmalucence Photogen Technologies Inc. Pierre Fabre Laboratories Pola Pharma Portal Instruments Promius Pharma Protagonist Therapeutics Provectus Biopharmaceuticals Rani Therapeutics Samsung Samsung Bioepis Sandoz Sanofi SFA Therapeutics Shire Sudo Biosciences Sun Pharma Suzhou Zelgen Biopharmaceuticals Takeda Taro Pharmaceutical Industries Teva Theravance Biopharma U.S. Department of Justice U.S. Federal Trade Commission UCB UNION Therapeutics URL Pharma Vanda Pharmaceuticals Viatris Vyne Therapeutics XBiotech Xbrane Biopharma Yangji Pharmaceutical Zydus Group |